STING Agonist ADC Scaffold for Targeted Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for diseases such as cancer and infectious diseases face challenges due to the inhibition of the STING activation process, leading to reduced efficacy and specificity, and there is a need for targeted immunotherapies that can modulate STING activity effectively.
Innovation Solution
Development of antibody-drug conjugates (ADCs) that include a STING agonist drug moiety linked to a protein-based recognition-molecule through a linker, designed to target and activate STING, enhancing its activity and providing therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-drug conjugates with STING agonists are used to target and activate STING, then immune response efficacy is improved, but treatment specificity and reliability deteriorate due to inhibition of the STING activation process in severe disease conditions
Solution Approach 1:
The ADC delivers the STING agonist directly to the target site through antibody-mediated targeting, performing the activation action before disease conditions can inhibit it. The conjugate structure ensures the agonist is delivered to the endoplasmic reticulum where STING is located, preempting inhibition by releasing the agonist at the precise location and timing needed for effective activation.
Solution Approach 2:
The antibody component acts as an intermediary that specifically targets the conjugate to cells expressing the relevant antigen, while the linker serves as an intermediary that controls the release of the STING agonist. This intermediary system ensures the agonist reaches its target despite inhibitory disease conditions, mediating between the delivery vehicle and the ultimate target.
2Reliability
If systemic administration of high doses is used to overcome STING inhibition, then therapeutic efficacy is improved, but toxicity increases
Solution Approach 1:
The ADC exhibits local quality by concentrating the STING agonist activity at the target site through antibody-mediated specific binding. The drug is delivered preferentially to cells expressing the target antigen, creating high local concentration where it is needed while maintaining low systemic concentration, thereby achieving effective therapy without systemic toxicity.
Solution Approach 2:
The therapeutic agent is segmented into three functional components: the antibody for targeted delivery, the linker for controlled release, and the STING agonist for immune activation. This segmentation allows the agonist to be delivered precisely to target cells rather than distributed systemically, achieving site-specific therapeutic effect without widespread toxicity.
3Adaptability or versatility
If non-specific cell population-based approaches are used for cancer therapy, then treatment coverage is improved, but specificity deteriorates
Solution Approach 1:
The antibody component provides universality by recognizing a specific antigen that may be expressed across different cancer cell types, allowing broad treatment coverage. Simultaneously, the STING agonist provides multi-functionality by activating innate immune pathways that can respond to various tumor antigens, combining broad coverage with mechanism-based specificity.
Solution Approach 2:
The ADC achieves local quality by targeting specific cells through antibody-antigen recognition rather than affecting all cells uniformly. The specific binding to antigen-expressing cells provides precise spatial localization of the therapeutic effect, distinguishing target cells from non-target cells while maintaining adaptability to different tumor types expressing the same antigen.
Data Source
AI summary
The present disclosure provides scaffolds and antibody-drug conjugates (ADCs) comprising a stimulator of interferon genes (STING). The present disclosure also provides uses of the ADCs in treatment, e.g., treatment of cancer.